Tuberculosis among patients treated with TNF-alpha blockers

Harefuah

Volumn 146, Issue 3, 2007, Pages 212-218

  Fuchs Polychuck, Inbal ^a,d   Avnon, Lone Slling ^b,d   Abu Shakra, Mahmoud ^c,d  

^a Department of Family Medicine ^*

^b Pulmonology Unit   (Israel)

^c Rheumatic Diseases Unit   (Israel)

^d BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

Anti TNF alpha; Latent tuberculosis; Rheumatoid arthritis; Tuberculin test; Tuberculosis

Indexed keywords

TUMOR NECROSIS FACTOR ALPHA;

CHEMICALLY INDUCED DISORDER; DRUG ANTAGONISM; HUMAN; RECURRENT DISEASE; REVIEW; RISK FACTOR; TUBERCULOSIS;

HUMANS; RECURRENCE; RISK FACTORS; TUBERCULOSIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 34547411842     PISSN: 00177768     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (39)

1. Maini R, St Clair EW, Breedveld F & al, Infliximab (chimeric anti-tumour necrosis factor a monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomized phase III trial. Lancet, 1999; 354: 1932-39.
2. Lipsky P, van der Heijde D, St Clair EW & al, Infliximab and Methotrexate in the treatment of rheumatoid arthritis. Antitumor necrosis factor trial in rheumatoid arthritis with concomitant therapy Study Group. NEJM, 2000; 343: 1594-1602.
3. Criscione L St & Clair EW, Tumor necrosis factor-antagonists for the treatment of rheumatic diseases. Curr Opin Rheumatol, 2002; 14: 204-11.
4. Choy EHS & Panayi GS, Cytokine pathways and joint inflammation in rheumatoid arthritis. NEJM, 2001; 344: 907-16.
5. Chu CO, Field M, Feldmann M & Maini RN, Localization of tumor necrosis factor alpha in synovial tissues and at the cartilage-pannus junction in patients with rheumatoid arthritis. Arthritis Rheum, 1991; 34: 1125-32.
6. Furst DE, Breedveld FC, Kalden JR & al, Updated consensus statement on biological agents for the treatment of rheumatic. Ann Rheum Dis, 2006; 65 S3: iii2-iii15.
7. Wallis RS, Broder M, Wong J & Beenhouwer D, Granulomatous infections due to tumor necrosis factor blockade. Clin. Infect Dis, 2004; 39: 1254-55.
8. Mufti A, Toye BW, Mckendry RR & Angel JB, Mycobacterium abscesses infection after the use of tumor necrosis factor a inhibitor therapy: case report and review of infectious complications associated with tumor necrosis factor α inhibitor use. Diag Microbiol Infect Dis, 2005; 53: 233-38.
9. Keane J, Gershon S, Wise RP & al, Tuberculosis associated with infliximab, a tumor necrosis factor - α-neutralizing agent. NEJM, 2001; 345: 1098-1104.
10. Bongartz T, Sutton AJ, Sweeting MJ & al, Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies. JAMA, 2006; 295: 2275-2285.
11. Dixon WG, Watson K, Lunt M & al, British Society for Rheumatology Biologics Register. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum, 2006; 54: 2368-76.
12. Wagner TE, Huseby ES & Huseby JS, Exacerbation of Mycobacterium tuberculosis enteritis masquerading as Crohn's disease after treatment with a tumour necrosis-α inhibitor. Am J Med, 2002; 112: 67-69.
13. Arend SM, Breedveld F & van Dissel T, TNF-α blockade and tuberculosis: better look before you leap. The Nether J Med, 2003; 61: 111-19.
14. Gomez-Reino J, Carmona L, Valverde VR & al, BIOBADASER Group. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk. Arthritis Rheum, 2003; 48: 2122-7.
15. Wolfe F, Michaud K, Anderson J & Urbansky K, Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy. Arthritis Rheum, 2004; 50: 372-9.
16. Askling J, Fored M, Brandt L & al, Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor-α antagonists in Sweden. Arthritis Rheum, 2005; 52: 1986-92.
17. Bean AG, Roach DR, Briscoe H & al, Structural deficiencies in granuloma formation in TNF gene-targeted mice underlie the heightened susceptibility to aerosol Mycobacterium tuberculosis infection which is not compensated for by lymphotoxin. J Immunol, 1999; 162: 3504-11.
18. Wallis RS, Broder M, Wong J & al, Reactivation of latent granulomatous infections by infliximab. Clin Infect Dis, 2005; 41 Suppl 3: S194-8.
19. Stenger S, Immunological control of tuberculosis: role of tumour necrosis factor and more. Ann Rheum Dis, 2005; 64 (Suppl 4): iv24-8.
20. Flynn J, Goldstein MM, Chan J & al, Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice. Immunity, 1995; 2: 561-72.
21. st edition. Amsterdam, the Netherlands, 2004, pp 623-628.
22. Mohan VP, Scanga CA, Yu K & al, Effects of tumor necrosis factor alpha on host immune response in chronic persistent tuberculosis: possible role for limiting pathology. Infect Immun, 2001; 69: 1847-55.
23. Greene VW, Dolberg OT, Alkan ML & Schlaeffer F, Tuberculosis cases in the Negev 1978-1987: ethnicity, sex, and age. Public Health Rev, 1992; 53-60.
24. Long R & Gardam M, Tumor necrosis factor alpha inhibitors and the reactivation of latent tuberculosis infection. Can Med Assoc J, 2003; 168: 1153-6.
25. American Thoracic Society. Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med, 2000; 161: S221-47.
26. Jasmer RM, Nahid P & Hopewell PC, Clinical practice. Latent tuberculosis infection. N Engl J Med, 2002; 347: 1860-6.
27. Wang L, Turner MO, Elwood RK & al, A meta-analysis of the effect of Bacille Calmette Guerin vaccination on tuberculin skin test measurement. Thorax, 2002; 57: 804-9.
28. CDC, Prevention and control of tuberculosis in correctional and detention facilities: recommendations from CDC, Department of Health and Human Services; MMWR July 2006.
29. Mow WS, Abreu-Martin MT, Papadakis KA & al, High incidence of anergy in inflammatory bowel disease patients limits the usefulness of PPD screening before infliximab therapy. Clin Gastroenterol Hepatol, 2004; 2: 309-13.
30. British Thoracic Society Standards of Care Committee. BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-alpha treatment. Thorax, 2005; 60: 800-805.
31. Ferrara G, Losi M, D'Amico R & al, Use in routine clinical practice of two commercial blood tests for diagnosis of infection with Mycobacterium tuberculosis: a prospective study. Lancet, 2006; 367: 1328-34.
32. Liebeschuetz S, Bamber S, Ewer K & al, Diagnosis of tuberculosis in South African children with a T-cell based assay: a prospective cohort study. Lancet, 2004; 363: 2196-203.
33. Brock I, Ruhwald M, Lundgren B & al, Latent tuberculosis in HIV positive, diagnosed by the M. tuberculosis specific interferon-gamma test. Respir Res, 2006; 7: 56.
34. Gardam MA, Keyston EC, Menzies R & al, Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect Dis, 2003; 3: 148-55.
35. Carmona L, Gomez-Reino JJ, Rodriguez-Valverde V & al, Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum, 2005; 52: 1766-72.
36. Salmon D, GTI and AFSSAPS. Groupe Tuberculose et infliximab. Agence Francaise de Securite Sanitaire de Produits de Sante. Recommendations about the prevention and management of tuberculosis in patients taking infliximab. Joint Bone Spine, 2002; 69: 170-2.
37. Shatin D, Rawson NS, Curtis JR & al, Documented tuberculin skin testing among infliximab users following a multi-modal risk communication intervention. Pharmacoepidemiol Drug Saf, 2006; 15: 8-11.
38. Smieja MJ, Marchetti CA, Cook DJ & al, Isoniazid for preventing tuberculosis in non-HIV infected persons (Cochrane Review). In: The Cochrane Library, Issue 2, 2004 (I)
39. Vlachaki E, Psathakis K, Tsintiris K & Iliopoulos A, Delayed response to anti-tuberculosis treatment in a patient on infliximab. Respir Med, 2005; 99: 1620-22.